After a quiet period in 2024, biopharma M&A activity is returning steadily, driven in part by strategic portfolio repositioning across Big Pharma. Buyers are prioritizing assets that fill pipeline gaps or add adjacent commercial revenue streams, particularly in areas such as oncology and precision medicine, obesity and metabolic disease, cardiovascular and renal disease, and CNS.

In an interview with Pharmaceutical Executive, Managing Partner Michael Abrams shared that pricing pressure, regulation, tariffs, and potential marketing rule changes are causing companies to think more carefully about where and how they deploy capital in 2026.

There’s a lot in motion. [But] it could be a good thing. The challenge for these big companies will be to come up with the will to change the way they work. I think a lot of that has just been frozen in place for a long time.

Read the full article at PharmExec.com.